CuraTeQ Clears Health Canada for Bevacizumab Biosimilar Bevqolva

CuraTeQ Biologics, the biosimilar arm of Aurobindo Pharma, has received a Notice of Compliance from Health Canada for Bevqolva, its bevacizumab biosimilar, securing marketing authorisation in Canada. For Indian biosimilar manufacturers tracking entry pathways into regulated Western markets, the approval signals that Health Canada's rigorous NOC process is navigable for emerging-market sponsors with the right clinical and CMC dossier depth.

Bevacizumab, a VEGF-targeting monoclonal antibody used across multiple oncology indications, sits in one of the most contested biosimilar categories globally. Canadian market access for a biosimilar in this class requires demonstrating analytical similarity, pharmacokinetic equivalence, and clinical comparability to the reference biologic under Health Canada's guidance framework. A Notice of Compliance confirms that CuraTeQ's submission met those evidentiary standards.

Regulatory and operational implications: For QA directors and regulatory affairs leads at biosimilar manufacturers, the approval underscores the strategic value of building dossiers capable of satisfying multiple stringent jurisdictions. Health Canada's NOC pathway, while distinct from the EMA's or FDA's biosimilar routes, carries comparable scientific rigour, and a successful filing here can inform submission strategies for other regulated markets. Plant heads overseeing biologics manufacturing should note that sustained GMP compliance across the product lifecycle, consistent with ICH Q10 principles, remains a prerequisite for maintaining any market authorisation once granted.

Competitive context: The oncology biosimilar space, particularly for bevacizumab, already includes approved competitors in major markets. CuraTeQ's Canadian approval adds another entrant to a category where formulary positioning, interchangeability designations, and tender pricing will determine commercial outcomes. Healthcare providers and payers in Canada will have an additional option as procurement decisions evolve.

Source: Indian Pharma Post, reporting on a Media4Growth release, published 3 May 2026.